Changes of the serum level of IL-1 receptor antagonist (IL-1ra) in the patients with type C chronic hepatitis during interferon therapy

International Hepatology Communications

Volumn 5, Issue 4-5, 1996, Pages 274-281

  Ohkawa, Yasuhiko ^a   Takahashi, Hiroki ^a   Zeniya, Mikio ^a   Aizawa, Yoshio ^a   Sakaguchi, Masami ^a   Toda, Gotaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Interferon therapy; Interleukin 1 receptor antagonist (IL 1ra)

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0030249226     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-4346(96)00308-8     Document Type: Article

References (20)

1. [1] Kanai K, Kato K, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
2. [2] Mita E, Hayashi N, Hagiwara H et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-982.
3. [3] Tilg H, Wilmer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-274.
4. [4] Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-1451.
5. [5] Robert JS, Jia EC, Laurel MS et al. Biological effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991; 34: 78-83.
6. [6] Seckinger P, Klein-Nulend J, Alander C et al. Natural and recombinant IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990; 145: 4181-4184.
7. [7] Tilg H, Mier JW, Vogel W et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993; 150: 4687-4692.
8. [8] Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-679.
9. [9] Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-883.
10. [10] Battegay M, Fikes J, Di-Bisceglie AM et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69: 2462-2470.
11. [11] Dripps Dj, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331-10336
12. [12] Malyak M, Swaney RT and Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993; 36: 781-789.
13. [13] Casini-Raggi V, Kam L, Chong YJT et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. J Immunol 1995; 154: 2434-2440.
14. [14] Tomar RH. Breaking the asymptomatic phase of HIV-1 infection. J Clin Lab Anal 1994; 8: 116-119.
15. [15] Tilg H, Vogel W, Wiedermann CJ et al. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology 1993; 18: 1132-1138.
16. [16] Jenkins JK, Malyak M, Arend WP. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 1994; 13: 47-54.
17. [17] Kuzushita N, Hayashi N, Katayama Y et al. Serum level of IL-10 and sICAM-1 in patients with chronic hepatitis C treated with interferon-alpha. Hapatology 1995; 22: 292A.
18. [18] Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin-1 or an interleukin-1 inhibitor. J Immunol 1985; 134: 3868-3875.
19. [19] Zeniya M, Hara M, Aizawa Y et al. HCV-RNA contained C3d binding immune complex in the serum of type C chronic hepatitis reflects the severity of the disease and relates to sicca syndrome. Hepatology 1994; 20: 252A.
20. [20] Tomiya T, Hayashi S, Yanase M et al. Circulating immune complex of hepatitis virus C in patients with acute and chronic hepatitis C. Hepatology 1994; 20: 252A.